Madhu Kumar
Stock Analyst at Goldman Sachs
(2.90)
# 1,634
Out of 4,955 analysts
150
Total ratings
56.44%
Success rate
20.45%
Average return
Main Sectors:
Stocks Rated by Madhu Kumar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JAZZ Jazz Pharmaceuticals | Initiates: Buy | $169 | $120.57 | +40.17% | 7 | Jun 5, 2024 | |
| FULC Fulcrum Therapeutics | Maintains: Neutral | $5 → $6 | $6.61 | -9.23% | 8 | Jan 26, 2024 | |
| INFA Informatica | Maintains: Neutral | $23 → $26 | $24.73 | +5.16% | 5 | Dec 7, 2023 | |
| UTZ Utz Brands | Maintains: Neutral | $19 → $17 | $12.97 | +31.07% | 2 | Nov 10, 2023 | |
| ALEC Alector | Initiates: Sell | $4 | $2.14 | +86.81% | 4 | Sep 25, 2023 | |
| KRYS Krystal Biotech | Maintains: Buy | $135 → $155 | $146.72 | +5.64% | 13 | May 22, 2023 | |
| CYTK Cytokinetics | Maintains: Buy | $48 → $53 | $38.10 | +39.11% | 4 | May 5, 2023 | |
| DSGN Design Therapeutics | Upgrades: Neutral | n/a | $4.97 | - | 3 | May 4, 2023 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Buy | $65 → $73 | $20.41 | +257.67% | 10 | May 3, 2023 | |
| APLS Apellis Pharmaceuticals | Maintains: Buy | $124 → $141 | $26.96 | +423.00% | 9 | Apr 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $39 → $34 | $15.65 | +117.25% | 6 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $20 → $6 | $2.52 | +138.57% | 8 | Dec 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $8 → $14 | $17.19 | -18.56% | 6 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $24 → $21 | $11.06 | +89.87% | 2 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $5 | $14.02 | -64.34% | 3 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $10 → $8 | $2.74 | +191.97% | 4 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $111 → $89 | $7.20 | +1,136.11% | 4 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $580 → $120 | $7.38 | +1,526.02% | 1 | Jan 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $10 | $0.49 | +1,940.82% | 1 | Aug 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $60 → $85 | $10.18 | +734.97% | 7 | Jun 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $23 → $39 | $2.75 | +1,318.18% | 3 | Mar 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $58 → $57 | $15.50 | +267.74% | 3 | Jul 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.53 | - | 15 | Jul 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $900 | $1.59 | +56,503.77% | 1 | Apr 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $17 → $20 | $4.38 | +357.14% | 2 | Mar 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $140 → $100 | $0.95 | +10,426.32% | 5 | Mar 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $35 | $33.91 | +3.21% | 1 | Mar 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $60 | $0.27 | +22,113.99% | 1 | Feb 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $58 → $40 | $11.36 | +252.11% | 2 | Sep 24, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $504 | $26.30 | +1,816.35% | 3 | Oct 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $210 → $230 | $466.84 | -50.73% | 2 | Aug 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $150 → $1,125 | $14.04 | +7,912.82% | 2 | Feb 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $40 | $0.88 | +4,471.43% | 1 | Feb 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $22 | $28.43 | -24.36% | 1 | Dec 1, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $52.68 | -55.39% | 1 | Mar 28, 2017 |
Jazz Pharmaceuticals
Jun 5, 2024
Initiates: Buy
Price Target: $169
Current: $120.57
Upside: +40.17%
Fulcrum Therapeutics
Jan 26, 2024
Maintains: Neutral
Price Target: $5 → $6
Current: $6.61
Upside: -9.23%
Informatica
Dec 7, 2023
Maintains: Neutral
Price Target: $23 → $26
Current: $24.73
Upside: +5.16%
Utz Brands
Nov 10, 2023
Maintains: Neutral
Price Target: $19 → $17
Current: $12.97
Upside: +31.07%
Alector
Sep 25, 2023
Initiates: Sell
Price Target: $4
Current: $2.14
Upside: +86.81%
Krystal Biotech
May 22, 2023
Maintains: Buy
Price Target: $135 → $155
Current: $146.72
Upside: +5.64%
Cytokinetics
May 5, 2023
Maintains: Buy
Price Target: $48 → $53
Current: $38.10
Upside: +39.11%
Design Therapeutics
May 4, 2023
Upgrades: Neutral
Price Target: n/a
Current: $4.97
Upside: -
Arrowhead Pharmaceuticals
May 3, 2023
Maintains: Buy
Price Target: $65 → $73
Current: $20.41
Upside: +257.67%
Apellis Pharmaceuticals
Apr 14, 2023
Maintains: Buy
Price Target: $124 → $141
Current: $26.96
Upside: +423.00%
Mar 1, 2023
Maintains: Buy
Price Target: $39 → $34
Current: $15.65
Upside: +117.25%
Dec 9, 2022
Downgrades: Neutral
Price Target: $20 → $6
Current: $2.52
Upside: +138.57%
Nov 10, 2022
Maintains: Sell
Price Target: $8 → $14
Current: $17.19
Upside: -18.56%
Nov 4, 2022
Maintains: Buy
Price Target: $24 → $21
Current: $11.06
Upside: +89.87%
Aug 25, 2022
Downgrades: Sell
Price Target: $5
Current: $14.02
Upside: -64.34%
May 24, 2022
Maintains: Sell
Price Target: $10 → $8
Current: $2.74
Upside: +191.97%
May 24, 2022
Maintains: Buy
Price Target: $111 → $89
Current: $7.20
Upside: +1,136.11%
Jan 19, 2022
Downgrades: Neutral
Price Target: $580 → $120
Current: $7.38
Upside: +1,526.02%
Aug 27, 2021
Downgrades: Sell
Price Target: $10
Current: $0.49
Upside: +1,940.82%
Jun 23, 2021
Maintains: Neutral
Price Target: $60 → $85
Current: $10.18
Upside: +734.97%
Mar 16, 2021
Upgrades: Outperform
Price Target: $23 → $39
Current: $2.75
Upside: +1,318.18%
Jul 31, 2020
Upgrades: Outperform
Price Target: $58 → $57
Current: $15.50
Upside: +267.74%
Jul 24, 2020
Downgrades: Neutral
Price Target: n/a
Current: $3.53
Upside: -
Apr 21, 2020
Initiates: Outperform
Price Target: $900
Current: $1.59
Upside: +56,503.77%
Mar 27, 2020
Maintains: Underperform
Price Target: $17 → $20
Current: $4.38
Upside: +357.14%
Mar 13, 2020
Maintains: Buy
Price Target: $140 → $100
Current: $0.95
Upside: +10,426.32%
Mar 12, 2020
Initiates: Outperform
Price Target: $35
Current: $33.91
Upside: +3.21%
Feb 11, 2020
Initiates: Outperform
Price Target: $60
Current: $0.27
Upside: +22,113.99%
Sep 24, 2019
Maintains: Buy
Price Target: $58 → $40
Current: $11.36
Upside: +252.11%
Oct 8, 2018
Upgrades: Buy
Price Target: $504
Current: $26.30
Upside: +1,816.35%
Aug 13, 2018
Maintains: Buy
Price Target: $210 → $230
Current: $466.84
Upside: -50.73%
Feb 9, 2018
Maintains: Buy
Price Target: $150 → $1,125
Current: $14.04
Upside: +7,912.82%
Feb 8, 2018
Initiates: Buy
Price Target: $40
Current: $0.88
Upside: +4,471.43%
Dec 1, 2017
Reinstates: Buy
Price Target: $22
Current: $28.43
Upside: -24.36%
Mar 28, 2017
Initiates: Buy
Price Target: $24
Current: $52.68
Upside: -55.39%